Avalo Therapeutics Files 2024 10-K

Ticker: AVTX · Form: 10-K · Filed: Mar 20, 2025 · CIK: 1534120

Avalo Therapeutics, INC. 10-K Filing Summary
FieldDetail
CompanyAvalo Therapeutics, INC. (AVTX)
Form Type10-K
Filed DateMar 20, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: 10-K, pharmaceutical, financials

Related Tickers: AVTX

TL;DR

AVTX filed its 2024 10-K. Check financials.

AI Summary

Avalo Therapeutics, Inc. filed its 2024 10-K on March 20, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Cerecor Inc. until November 2, 2011, is based in Rockville, MD. The filing details its financial position and business operations for the period.

Why It Matters

This filing provides investors and stakeholders with a comprehensive overview of Avalo Therapeutics' financial health and operational performance for the fiscal year 2024, crucial for investment decisions.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Avalo Therapeutics is subject to inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

Key Players & Entities

FAQ

What is the primary business of Avalo Therapeutics, Inc.?

Avalo Therapeutics, Inc. is in the Pharmaceutical Preparations industry, as indicated by its SIC code [2834].

When did Avalo Therapeutics, Inc. change its name from Cerecor Inc.?

The company changed its name from Cerecor Inc. on November 2, 2011.

Where is Avalo Therapeutics, Inc. located?

Avalo Therapeutics, Inc. is located at 540 Gaither Road, Suite 400, Rockville, MD 20850.

What is the SEC file number for Avalo Therapeutics, Inc.?

The SEC file number for Avalo Therapeutics, Inc. is 001-37590.

What period does this 10-K filing cover?

This 10-K filing covers the fiscal year ending December 31, 2024.

Filing Details

This Form 10-K (Form 10-K) was filed with the SEC on March 20, 2025 regarding Avalo Therapeutics, Inc. (AVTX).

View full filing on EDGAR

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing